Search filters

List of works by Jeffrey S Weber

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

scientific article published on 20 December 2016

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

scientific article published on 10 September 2017

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

scientific article published on 22 October 2019

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)

Association between intraepithelial Escherichia coli and colorectal cancer ⬇️

scientific article published on 01 August 1998

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

scientific article published on 11 January 2019

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

scientific article published on 12 March 2019

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

scientific article published on 14 February 2019

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Classification of current anticancer immunotherapies

scientific article

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

scientific article published on 17 August 2016

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

scientific article published on 27 December 2015

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.

scientific article published on 2 March 2018

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

scientific article

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

scientific article

Comment on the American Society of Clinical Oncology Value Statement

scientific article published on 13 June 2016

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

scientific article published on 01 June 2019

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function ⬇️

scientific article published on April 1, 2011

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

scientific article published on 21 August 2018

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

scientific article

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

scientific article published on 01 April 2019

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials ⬇️

scientific article published on May 10, 2013

From the Guest Editor: Adoptive Cell Therapy: Fulfilling Its Promise

scientific article published on 01 November 2015

Frontiers in pigment cell and melanoma research

scientific article published on 03 October 2018

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

scientific article published on 06 February 2019

Immune regulatory antibodies: are they the next advance?

scientific article published on July 2010

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

scientific article published on 15 January 2018

Immunotherapy in the adjuvant setting for high-risk melanoma

scientific article published on 01 August 2018

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.

scientific article published on 16 March 2016

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

scientific article published on 01 April 2020

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

scientific article published on 20 October 2010

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

scientific article published on 9 October 2017

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

scientific article published on 01 July 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

scientific article published on 14 February 2018

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition

scientific article published on 24 January 2020

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy

scientific article published on 25 February 2020

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

scientific article published on 11 May 2017

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

scientific article published on 7 October 2015

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

scientific article

Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy

scientific article published in January 2017

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

scientific article

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

scientific article

PD-1 and PD-L1 antibodies in cancer: current status and future directions

scientific article published on 17 February 2017

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

scientific article published on 20 March 2019

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

scientific article published on 12 February 2016

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application

scientific article published on 01 October 2018

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy

scientific article published on 01 February 2019

Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors

scientific article published on 9 February 2018

Recent advances in adjuvant therapy for patients with melanoma.

scientific article

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

scientific article published on 09 October 2019

Reply to F. Liang et al.

scientific article published on 6 March 2017

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes

scientific article published on November 2016

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

scientific article published on 30 December 2016

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis

scientific article published on 22 January 2020

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

scientific article published on 10 September 2014

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

scientific article published on 26 May 2017

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

scientific article published on 26 February 2020

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

scientific article published on 01 May 2020

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

scientific article published on 9 November 2017

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

scientific article published on 19 August 2019

WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression.

scientific article published on 10 November 2017

Paulina is supported by:

About Paulina

Help